Johnson & Johnson vs Monster Beverage Corp — how do they compare? Johnson & Johnson trades at $261.07 (market cap $618.09B), while Monster Beverage Corp trades at $43.67 (market cap $85.51B). The key difference: Johnson & Johnson is far larger — about 7.2× Monster Beverage Corp's market cap, and Johnson & Johnson pays a 2.09% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Monster Beverage Corp for 72 Days on average.
| JNJ | MNST | |
|---|---|---|
Market Cap | $618.09B | $85.51B |
Volume | 6,050,983 | 8,569,709 |
Sector | Health | Consumer Staples |
52-Week High | $278.43 | $49.97 |
52-Week Low | $186.00 | $33.16 |
Typical Hold Time | 129 Days | 72 Days |
Enterprise Value | $646.37B | $83.81B |
Dividend Yield | 2.09% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Monster Beverage (MNST) trades at $43.58, up 1.63% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust profitability with a net margin of 23.08% and zero long-term debt. Recent news highlights international sales growth of 35% in Q2 and a 1:2 stock split effective August 2026.
Outlook remains positive with a consensus price target of $98.22, implying significant upside, supported by international expansion and a debt-free balance sheet. Risks include competitive pressures, regulatory challenges in markets like India, and rich valuation multiples such as a P/E of 40.42. Analyst consensus is bullish with 52% buy ratings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →